JAK/STAT Signaling


Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
-
BA2753 SD-36Summary: SD-36 is an effective degradant (=~50nM) with high selectivity compared to other members. -
BA2797 STAT3-IN-1Summary: STAT3-IN-1 is a potent, selective, and orally effective inhibitor with values of 1.82 μM and 2.14 μM in HT29 and MDA-MB231 cells, respectively. -
BA2806 SC-43Summary: SC-43, a derivative of Sorafenib, is a potent agonist with oral activity. -
BA2881 AG-825Summary: AG-825 is a selective, ATP-competitive, inhibitor of tyrosine phosphorylation. -
BA2996 UC-514321Summary: A selective TET1 inhibitor -
C8406 LomedeucitinibSummary: Lomedeucitinib (BMS-986322) acts by targeting receptor tyrosine protein kinases. -
A9916 Fedratinib hydrochloride hydrateSummary: A JAK2 inhibitor -
BA4122 GivinostatSummary: Inhibitors. -
BA6006 CirsilineolSummary: Cirsilineol is a natural flavonoid compound that selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal T cells. -
BA6391 DHFR-IN-4Summary: DHFR-IN-4 is a potent dihydrofolate reductase inhibitor.

